NANOBAKTERİ: PERİODONTAL VE SİSTEMİK HASTALIKLARIN İLİŞKİSİNDE FARKLI BİR BAKIŞ AÇISI

Abstract

Nanobakteriler, sıra dışı biçimde küçük boyutlara sahip (50-500 nm), pleomorfik, infeksiyöz, patojenik varlıklar olarak tarif edilmiş ve patogenezlerinde iskelet dışı kalsifikasyonlar bulunan pek çok sistemik hastalıkla ilişkilendirilmiştir. Periodontal hastalığın temel nedeni olan dental plak, bu tip kalsifikasyonlara benzer bir süreçle mineralize olmaktadır ve kalkulus yapısını oluşturmaktadır. Patolojik kalsifikasyonlarında önemli rol oynadıkları varsayılan nanobakterilerin dental kalkulus oluşumuna katkı sağladığı ve periodontal hastalıklar açısından risk oluşturduğu düşünülmektedir. Bu derlemede nanobakterilerin, periodontal hastalıkların patogenezindeki ve sistemik hastalıklar ile ilişkisindeki olası rolü özetlenmiştir.

Keywords

• Nanobakteri
• periodontal hastalık
• patogenez

NANOBACTERIA: A DIFFERENT POINT OF VIEW TO THE RELATIONSHIP BETWEEN PERIODONTAL AND SYSTEMIC DISEASES

Abstract

Nanobacteria have been described as unusually small sized (50-500 nm), pleomorphic, infectious, pathogenic entities and associated with several systemic diseases having extra-skeletal calcifications in their pathogenesis. Dental plaque as the main cause for periodontal disease minerilizes through a process similar to these calcifications and forms calculus. Nanobacteria, considered to be playing a major role in pathologic calcifications, might be participating in dental calculus formation and consisting a risk factor for periodontal diseases. Possible role of nanobacteria in periodontal diseases' pathogenesis and interrelationship with systemic diseases have been summarized in this review.

Keywords

• Nanobacteria
• periodontal disease
• pathogenesis

References

1. Kajander EO, Ciftcioglu N. Nanobacteria: an alternative mechanism for pathogenic intra– and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 1998; 95(14):8274–8279.
2. Urbano P, Urbano F. Nanobacteria: facts or fancies? PLoS Pathog 2007; 3(5):e55.
3. Young JD, Martel J, Young L et al. Putative nanobacteria represent physiological remnants and culture by–products of normal calcium homeostasis. PLoS One 2009; 4(2):e4417.
4. Kajander EO, Ciftcioglu N, Aho K et al. Characteristics of nanobacteria and their possible role in stone formation. Urol Res 2003; 31(2):47–54.
5. Sommer AP, Oron U, Pretorius AM et al. A preliminary investigation into light–modulated replication of nanobacteria and heart disease. J Clin Laser Med Surg 2003; 21(4):231–235.
6. Martel J, Wu CY, Young JD. Critical evaluation of gamma–irradiated serum used as feeder in the culture and demonstration of putative nanobacteria and calcifying nanoparticles. PLoS One 2010; 5(4):e10343.
7. Young JD, Martel J. The rise and fall of nanobacteria. Sci Am 2010; 302(1):52–59.
8. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000 2002; 28:12–55.

9. Abraham J, Grenon M, Sanchez HJ et al. A case study of elemental and structural composition of dental calculus during several stages of maturation using SRXRF. J Biomed Mater Res A 2005; 75(3):623– 628.
10. Demir T. Is there any relation of nanobacteria with periodontal diseases? Med Hypotheses 2008; 70(1):36–39.
11. Zhang SM, Tian F, Jiang XQ et al. Evidence for calcifying nanoparticles in gingival crevicular fluid and dental calculus in periodontitis. J Periodontol 2009; 80(9):1462–1470.
12. Abraham J, Grenon M, Sanchez HJ et al. Spectrochemical analysis of dental calculus by synchrotron radiation X–ray fluorescence. Anal Chem 2002; 74(2):324–329.
13. White DJ. Dental calculus: recent insights into occurrence, formation, prevention, removal and oral health effects of supragingival and subgingival deposits. Eur J Oral Sci 1997; 105(5 Pt 2):508–522.
14. Hung HC, Willett W, Merchant A et al. Oral health and peripheral arterial disease. Circulation 2003; 107(8):1152–1157.
15. Higashi Y, Goto C, Hidaka T et al. Oral infection– inflammatory pathway, periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. Atherosclerosis 2009; 206(2):604– 610.
16. Ford PJ, Raphael SL, Cullinan MP et al. Why should a doctor be interested in oral disease? Expert Rev Cardiovasc Ther 2010; 8(10):1483–1493.
17. Cotti E, Dessi C, Piras A et al. Can a chronic dental infection be considered a cause of cardiovascular disease? A review of the literature. Int J Cardiol 2011; 148(1): 4–10.
18. Hayashi C, Gudino CV, Gibson FC, 3rd et al. Review: Pathogen–induced inflammation at sites distant from oral infection: bacterial persistence and induction of cell–specific innate immune inflammatory pathways. Mol Oral Microbiol 2010; 25(5):305–316.
19. Zaremba M, Gorska R, Suwalski P et al. Evaluation of the incidence of periodontitis–associated bacteria in the atherosclerotic plaque of coronary blood vessels. J Periodontol 2007; 78(2):322–327.
20. Carallo C, Fortunato L, de Franceschi MS et al. Periodontal disease and carotid atherosclerosis: are hemodynamic forces a link? Atherosclerosis 2010; 213(1):263–267.
21. Nakib SA, Pankow JS, Beck JD et al. Periodontitis and coronary artery calcification: the Atherosclerosis Risk in Communities (ARIC) study. J Periodontol 2004; 75(4):505–510.
22. Ciftcioglu N, McKay DS, Kajander EO. Association between nanobacteria and periodontal disease. Circulation 2003; 108(8):e58–9; author reply e58–59.
23. Miller VM, Rodgers G, Charlesworth JA et al. Evidence of nanobacterial–like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol 2004; 287(3):H1115–1124.
24. Puskas LG, Tiszlavicz L, Razga Z et al. Detection of nanobacteria–like particles in human atherosclerotic plaques. Acta Biol Hung 2005; 56(3–4):233–245.
25. Jelic TM, Malas AM, Groves SS et al. Nanobacteria– caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J 2004; 97(2):194– 198.
26. Hu YR, Zhao Y, Sun YW et al. Detection of nanobacteria–like material from calcified cardiac valves with rheumatic heart disease. Cardiovasc Pathol 2010; 19(5):286–292.
27. Nadeem M, Stephen L, Schubert C et al. Association between periodontitis and systemic inflammation in patients with end–stage renal disease. SADJ 2009; 64(10):470–473.
28. Dag A, Firat ET, Kadiroglu AK et al. Significance of elevated gingival crevicular fluid tumor necrosis factor–alpha and interleukin–8 levels in chronic hemodialysis patients with periodontal disease. J Periodontal Res 2010; 45(4):445–450.
29. Madore F. Periodontal disease: a modifiable risk factor for cardiovascular disease in ESRD patients? Kidney Int 2009; 75(7):672–674.
30. Kshirsagar AV, Offenbacher S, Moss KL et al. Antibodies to periodontal organisms are associated with decreased kidney function. The Dental Atherosclerosis Risk In Communities study. Blood Purif 2007; 25(1):125–132.
31. Khullar M, Sharma SK, Singh SK et al. Morphological and immunological characteristics of nanobacteria from human renal stones of a north Indian population. Urol Res 2004; 32(3):190–195.
32. Hjelle JT, Miller–Hjelle MA, Poxton IR et al. Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int 2000; 57(6):2360–2374.
33. Shiekh FA, Khullar M, Singh SK. Lithogenesis: induction of renal calcifications by nanobacteria. Urol Res 2006; 34(1):53–57.
34. Kajander EO, Ciftcioglu N, Miller–Hjelle MA et al. Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Nephrol Hypertens 2001; 10(3):445–452.
35. 35. Shoskes DA, Thomas KD, Gomez E. Anti– nanobacterial therapy for men with chronic prostatitis/ chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol 2005; 173(2):474– 477.
36. Zhou Z, Hong L, Shen X et al. Detection of nanobacteria infection in type III prostatitis. Urology 2008; 71(6):1091–1095.
37. de Pablo P, Chapple IL, Buckley CD et al. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol 2009; 5(4):218–224.
38. Berthelot JM, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine 2010; 77(6):537–541.
39. Ogrendik M. Rheumatoid arthritis is linked to oral bacteria: etiological association. Mod Rheumatol 2009; 19(5):453–456.
40. Bozkurt FY, Yetkin Ay Z, Berker E et al. Anti– inflammatory cytokines in gingival crevicular fluid in patients with periodontitis and rheumatoid arthritis: a preliminary report. Cytokine 2006; 35(3–4):180–185.
41. Tsurumoto T, Matsumoto T, Yonekura A et al. Nanobacteria–like particles in human arthritic synovial fluids. J Proteome Res 2006; 5(5):1276– 1278.
42. Eskandary H, Saba M, Yazdi T. Nanobacteria and intervertebral disc degeneration. Med Hypotheses 2005; 65(5):997–998.
43. Smolik I, Robinson D, El–Gabalawy HS. Periodontitis and rheumatoid arthritis: epidemiologic, clinical, and immunologic associations. Compend Contin Educ Dent 2009; 30(4):188–90, 192, 194 passim; quiz 198, 210.
44. Cappuyns I, Gugerli P, Mombelli A. Viruses in periodontal disease – a review. Oral Dis 2005; 11(4):219–229.
45. Gonzalez OA, Ebersole JL, Huang CB. Oral infectious diseases: a potential risk factor for HIV virus recrudescence? Oral Dis 2009; 15(5):313–327.
46. Mataftsi M, Skoura L, Sakellari D. HIV infection and periodontal diseases: an overview of the post– HAART era. Oral Dis 2011;17(1): 13–25.
47. Pretorius AM, Sommer AP, Aho KM et al. HIV and nanobacteria. HIV Med 2004; 5(6):391–393.
48. Sommer AP. Peripheral neuropathy and light– preliminary report indicating prevalence of nanobacteria in HIV. J Proteome Res 2003; 2(6):665– 666.
49. Sommer AP. Could reduced bone mineral densities in HIV be caused by nanobacteria? J Proteome Res 2004; 3(3):670–672.
50. Cisar JO, Xu DQ, Thompson J et al. An alternative interpretation of nanobacteria–induced biomineralization. Proc Natl Acad Sci U S A 2000; 97(21):11511–11515.